drugset / Trial / NCT05635110

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

NCT05635110

Phase 1 Completed 31 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of VX-548 and its metabolite in the absence and presence of omeprazole or rifampin, in healthy participants.

Timeline

Start
2022-12-15
Primary completion
2023-06-08
Completion
2023-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Omeprazole Other / unclassified Oral
Subject Rifampin Small molecule Oral
Subject Suzetrigine Small molecule Oral

Indications

No indication recorded.